AGT pipeline boosted in merger with US firm
27 April, 2004 by Melissa TrudingerAGT Biosciences (ASX:AGT) has merged with US company ChemGenex Therapeutics to create a genomics-driven pharmaceutical company with two products in Phase II clinical trials.
Obesity drug alters brain, says scientist
23 April, 2004 by Staff WritersA British scientist has warned that Sanofi-Synthelabo's experimental obesity drug Acomplia could alter the way people think.
Queensland's Xenome files IND for painkiller
22 April, 2004 by Renate KrelleXenome -- 25 per cent owned by Medica Holdings (ASX:MCA) -- has filed an investigational new drug (IND) application with the US Food and Drug Administration for its Xen2174 cancer painkiller, which is derived from cone shell venom.
Biotechs, big pharma benefit as first P3 grants awarded
22 April, 2004 by Renate KrelleThe federal government has today ladled out just under 60 per cent of the funding for its five-year $150 million Pharmaceutical Partnerships Program -- known as P3 -- giving 11 pharmaceutical and biotech companies a cash boost to fund drug development.
Pharmaxis says study points to larger market for lung drug
21 April, 2004 by Renate KrelleSydney-based Pharmaxis (ASX:PXS) believes the market for its Aridol lung function test has the potential to double, after a pilot Swiss study gave Aridol the stamp of approval for predicting patients' response to steroids used to treat chronic obstructive pulmonary disease.
Proteome Systems to assist in Huntington's research
20 April, 2004 by Graeme O'NeillA US foundation that sponsors research into Huntington's disease has turned to Sydney proteomics company Proteome Systems to search for prognostic markers and targets for drugs to treat the fatal neurodegenerative disorder.
Meditech says Phase II trial shows early promise
20 April, 2004 by Renate KrelleMeditech (ASX:MTR) will enrol an additional 12 patients in its Phase II trial, following promising early results from its HyCAMP treatment for advanced colorectal cancer patients at the Royal Melbourne Hospital.
Prima encouraged by Biomira result
16 April, 2004 by Melissa TrudingerPrima Biomed (ASX:PRR) has been cheered by clinical trial results from commercial partner Biomira.
By the pricking of my thumbs: shark and crustacean extracts may fight osteoarthritis
15 April, 2004 by Graeme O'NeillCan an extract of shark cartilage and crustacean shells alleviate the pain and inflammation of symptoms of osteoarthritis, the most common disease of aging?
pSivida raises $21 million as clinical trials approach
15 April, 2004 by Melissa TrudingerPerth-based nanotechnology company pSivida (ASX: PSD) has raised $21 million in an international placement - enough cash to see the company through to 2006, when it expects its first revenues.
Glaxo award winner getting more out of LIF
15 April, 2004 by Melissa TrudingerProf Doug Hilton, a researcher at the Walter and Eliza Hall Institute in Melbourne, has been awarded this year's GlaxoSmithKline award for research excellence, for his work on cell signalling.
J&J profit jumps, earnings forecast raised
14 April, 2004 by Staff WritersJohnson & Johnson's first-quarter earnings have jumped 20 per cent on higher sales of prescription drugs and medical devices, prompting it to raise its full-year profit forecast.
Biotech Capital kicks off expansion plans with $3.8m buyback
14 April, 2004 by Renate KrelleShareholders of Biotech Capital (ASX:BTC) have approved a $3.8 million buyback of shares and options held by the Challenger Group.
Gradiflow graduates to validation stage
14 April, 2004 by Melissa TrudingerLife Technologies (formerly Gradipore, ASX: GDP) has announced that it has moved into the second phase of its development agreement with US company Hematech.
Biotech startup Epichem opens for business
13 April, 2004 by Melissa TrudingerState of the art medicinal chemistry facilities were opened on the Murdoch University campus by the WA Minister for Development Clive Brown last week for biotech start up Epichem.
